MedPath

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Phase 1
Completed
Conditions
HIV Infections
Registration Number
NCT00000902
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

The purpose of this study is to determine the value of changing anti-HIV medications in children with progressive HIV disease who have received previous treatment.

Plasma viral load (the level of HIV in the blood) is probably most effectively reduced by giving patients anti-HIV drugs which affect the virus at various stages of development. Changing the medications may enhance the results of treatment.

Detailed Description

The Master RAD Protocol is based on the concept that optimal suppression of viral load in vivo will be achieved in patients with rapidly progressing or advanced HIV disease (RAD) using antiretroviral combinations inhibiting viral replication at distinct sites of action. Antiretroviral combinations are chosen with the hypothesis that simultaneous change to as many new agents as possible is necessary to maximally reduce plasma viral load.

In this open-label, multicenter study patients are randomized into 1 of 4 groups based on prior antiretroviral experience. Each regimen consists of 4 drugs that include a combination of nucleoside reverse transcriptase inhibitors (stavudine, lamivudine, zidovudine, didanosine, zalcitabine) plus nevirapine (NVP), nelfinavir (NFV), or ritonavir (RTV). Patients must be naive to at least 2 of the 4 drugs in the regimen and at least 1 of the novel drugs must be NVP, NFV, or RTV.

Prior to randomization to a NFV- or RTV-containing regimen, patients are stratified by HIV RNA (greater than or equal to 50,000 or less than 50,000) and must able to receive 2 or more novel drugs.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
217
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (62)

Univ of Alabama at Birmingham - Pediatric

🇺🇸

Birmingham, Alabama, United States

Univ of South Alabama

🇺🇸

Mobile, Alabama, United States

UCSD Med Ctr / Pediatrics / Clinical Sciences

🇺🇸

La Jolla, California, United States

Long Beach Memorial (Pediatric)

🇺🇸

Long Beach, California, United States

Los Angeles County - USC Med Ctr

🇺🇸

Los Angeles, California, United States

Cedars Sinai / UCLA Med Ctr

🇺🇸

Los Angeles, California, United States

Harbor - UCLA Med Ctr / UCLA School of Medicine

🇺🇸

Los Angeles, California, United States

Children's Hosp of Oakland

🇺🇸

Oakland, California, United States

UCSF / Moffitt Hosp - Pediatric

🇺🇸

San Francisco, California, United States

Children's Hosp of Denver

🇺🇸

Denver, Colorado, United States

Scroll for more (52 remaining)
Univ of Alabama at Birmingham - Pediatric
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.